Advertisement

Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia

  • T.C Ooi
    Correspondence
    Corresponding author. Tel.: +1-613-761-4420; fax: +1-613-761-5316.
    Affiliations
    Metabolism and Hormone Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, 1053 Carling Avenue, Ottawa, Ont., Canada K1Y 4E9

    Division of Medical Biochemistry, Department of Laboratory Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, Ottawa, Ont., Canada
    Search for articles by this author
  • M Cousins
    Affiliations
    Metabolism and Hormone Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, 1053 Carling Avenue, Ottawa, Ont., Canada K1Y 4E9
    Search for articles by this author
  • D.S Ooi
    Affiliations
    Metabolism and Hormone Laboratory, Division of Endocrinology and Metabolism, Department of Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, 1053 Carling Avenue, Ottawa, Ont., Canada K1Y 4E9

    Division of Medical Biochemistry, Department of Laboratory Medicine, Ottawa Hospital, University of Ottawa, Civic Campus, Ottawa, Ont., Canada
    Search for articles by this author
  • K Nakajima
    Affiliations
    Otsuka America Pharmaceutical Inc., Rockville, MD, USA
    Search for articles by this author
  • A.L Edwards
    Affiliations
    Division of Endocrinology and Metabolism, University of Calgary, Calgary, Alta., Canada
    Search for articles by this author

      Abstract

      We have investigated the effect of standard doses of two fibrates, gemfibrozil and fenofibrate, on fasting and postprandial remnant-like particles (RLP) in subjects with combined hyperlipidemia. Forty-eight subjects participated; of these, 14 underwent a Vitamin A-fat loading test before and after 6 months of treatment with gemfibrozil (n=8) and fenofibrate (n=6). Blood was drawn every 2 h for 12 h after the test meal. The postprandial response was calculated as the area under the curve (AUC). There was no difference in fasting levels and pre-treatment AUC for triglycerides (TG), RLP cholesterol (RLP-C), RLP triglycerides (RLP-TG) and retinyl palmitate (RetP) between the two treatment groups. There was also no difference in the treatment effect on all parameters between the two treatment groups. Combining the two treatment groups, treatment resulted in a significant reduction in fasting levels and AUC of all four parameters. Assigning the difference observed between pre-treatment AUC of the combined study group and AUC of a normolipidemic (NL) control group as 100%, fibrate treatment resulted in decreases in AUC for TG, RLP-C, RLP-TG and RetP of 68, 69, 69 and 94%, respectively. These results indicate that fibrates are effective agents in reducing the postprandial increase in remnant lipoprotein particles.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schaefer E.J.
        • Gregg R.E.
        • Ghiselli G.
        • Forte T.M.
        • Ordovas J.M.
        • Zech L.A.
        • et al.
        Familial apolipoprotein E deficiency.
        J. Clin. Invest. 1986; 78: 1206-1219
        • Havel R.
        McCollum Award Lecture, 1993: Triglyceride-rich lipoproteins and atherosclerosis—new perspectives.
        Am. J. Clin. Nutr. 1994; 59: 795-799
        • Cohn J.S.
        • Marcoux C.
        • Davignon J.
        Detection, quantification and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 2474-2486
        • Hodis H.N.
        Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.
        Circulation. 1999; 99: 2852-2854
        • Nordestgaard B.G.
        • Zilversmit D.B.
        Comparison of arterial intimal clearances of LDL from diabetic and non-diabetic cholesterol-fed rabbits, differences in intimal clearance explained by size differences.
        Arteriosclerosis. 1989; 9: 176-183
        • Nordestgaard B.G.
        • Tybjaerg-Hansen A.
        • Lewis B.
        Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentration, extent of aortic lesion, and lipoprotein particle size as determinants.
        Arterioscler. Thromb. 1992; 12: 6-18
        • Campos E.
        • Nakajima K.
        • Tanaka A.
        • Havel R.J.
        Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.
        J. Lipid Res. 1992; 33: 369-380
        • Jialal I.
        • Devaraj S.
        Remnant lipoproteins: measurement and clinical significance.
        Clin. Chem. 2002; 48: 217-219
        • Karpe F.
        • Taskinen M.R.
        • Nieminen M.S.
        • Frick M.H.
        • Kesäniemi Y.A.
        • Pasternack A.
        • et al.
        Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.
        Atheroscelerosis. 2001; 157: 181-187
        • Deighan C.J.
        • Caslake M.J.
        • McConnell M.
        • Boulton-Jones J.M.
        • Packard C.J.
        Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.
        J. Chron. Soc. Nephrol. 2001; 12: 341-348
        • Tomizawa T.
        • Nakajima K.
        • Mori M.
        Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
        J. Atheroscler. Thromb. 2000; 7: 91-96
        • Simpson H.S.
        • Williamson C.M.
        • Olivecrona T.
        • Pringle S.
        • Maclean J.
        • Lorimer A.R.
        • et al.
        Postprandial lipemia, fenofibrate and coronary artery disease.
        Atherosclerosis. 1990; 85: 193-202
        • Simo I.E.
        • Yakichuk J.A.
        • Ooi T.C.
        Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
        Atheroscelerosis. 1993; 100: 55-64
        • Ooi T.C.
        • Cousins M.
        • Ooi D.S.
        • Steiner G.
        • Uffelman K.
        • Nakajima K.
        • et al.
        Postprandial remnant-like lipoproteins in hypertriglyceridemia.
        J. Clin. Endocrinol. Metab. 2001; 86: 3134-3142
        • Marcoux C.
        • Hopkins P.N.
        • Wang T.
        • Leary E.T.
        • Nakajima K.
        • Davignon J.
        • et al.
        Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state.
        J. Lipid Res. 2000; 41: 1428-1436
        • Dzavik V.
        • Ansquer J.C.
        • Delaval D.
        Micronised fenofibrate or gemfibrozil in patients with combined hyperlipidemia: a double-blind randomized multicentre trial.
        Atherosclerosis. 1999; 144: 32
        • Ooi T.C.
        • Simo I.E.
        • Yakichuk J.A.
        Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome.
        Arterioscler. Thromb. 1992; 12: 1184-1190
        • Nakajima K.
        • Saito T.
        • Tamura A.
        • Suzuki M.
        • Nakano T.
        • Adachi M.
        • et al.
        Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB100 and anti apoA1 immunoaffinity mixed gels.
        Clin. Chim. Acta. 1993; 223: 53-71
        • Weintraub M.S.
        • Eisenberg S.
        • Breslow J.L.
        Different patterns of postprandial lipoprotein metabolism in normal type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
        J. Clin. Invest. 1987; 79: 1110-1119
        • Björkegren J.
        • Packard C.J.
        • Hamsten A.
        • Bedford D.
        • Caslake M.
        • Sheperd J.
        • et al.
        Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway.
        J. Lipid Res. 1996; 37: 76-86
        • Stein D.T.
        • Devaraj S.
        • Balis D.
        • Adams-Huet B.
        • Jialal I.
        Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 2026-2031
        • Sasaki S.
        • Kuwahara N.
        • Kunitomo K.
        • Harada S.
        • Yamada T.
        • Azuma A.
        • et al.
        Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
        Am. J. Cardiol. 2002; 89: 386-389
        • Dane-Stewart C.A.
        • Watts G.F.
        • Mamo J.C.L.
        • Barrett P.H.
        • Martins I.J.
        • Dimmitt S.B.
        • et al.
        Effect of simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolemia.
        Eur. J. Clin. Invest. 2002; 32: 493-499
        • de Sauvage Nolting P.R.W.
        • Twickler M.B.
        • Dallinga-Thie G.M.
        • Buirma R.J.A.
        • Hutten B.A.
        • Kastelein J.J.P.
        Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
        Circulation. 2002; 106: 788-792
        • Twickler T.B.
        • Dallinga-Thie G.M.
        • de Valk H.W.
        • Schreuder P.C.N.J.
        • Jansen H.
        • Cabezas M.C.
        • et al.
        High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2422-2427
        • Schaefer E.J.
        • McNamara J.R.
        • Tayler T.
        • Daly J.A.
        • Gleason J.A.
        • Seman L.J.
        • et al.
        Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
        Am. J. Cardiol. 2002; 90: 689-696
        • Wilmink H.W.
        • Twickler M.B.
        • Banga J.D.
        • Dallinga-Thie G.M.
        • Eeltink H.
        • Erkelens D.W.
        • et al.
        Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.
        Cardiovasc. Res. 2001; 50: 577-582
        • McLaughlin T.
        • Abbasi F.
        • Lamendola C.
        • Leary E.
        • Reaven G.M.
        Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme A reductase inhibitor treatment of combined dyslipidemia.
        Metabolism. 2002; 51: 1355-1359
        • Ooi T.C.
        • Ooi D.S.
        The atherogenic significance of an elevated plasma triglyceride level.
        Crit. Rev. Clin. Lab. Sci. 1998; 35: 489-516
        • Phillips N.R.
        • Waters D.
        • Havel R.J.
        Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.
        Circulation. 1993; 88: 2762-2770
        • Krauss R.M.
        • Lindgren F.T.
        • Williams P.T.
        • Kelsey S.F.
        • Brensike J.
        • Vranizan K.M.
        • et al.
        Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men.
        Lancet. 1987; 2: 62-66
        • Blankenhorn D.H.
        • Alaupovic P.
        • Wickham E.
        • Chin H.P.
        • Azen S.P.
        Prediction of angiographic change in native human coronary arteries and aortacoronary bypass grafts. Lipid and non-lipid factors.
        Circulation. 1990; 81: 470-476
        • Hodis H.N.
        • Mack W.J.
        • Azen S.P.
        • Alaupovic P.
        • Pogoda J.M.
        • Labree L.
        • et al.
        Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
        Circulation. 1994; 90: 42-49
        • Alaupovic P.
        • Mack W.J.
        • Knight-Gibson C.
        • Hodis H.N.
        The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 715-722
        • Ericsson C.G.
        • Hamsten A.
        • Nilsson J.
        • Grip L.
        • Svane B.
        • de Faire U.
        Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
        Lancet. 1996; 347: 849-853
        • Tkác I.
        • Kimball B.P.
        • Lewis G.
        • Uffelman K.
        • Steiner G.
        The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3633-3638
        • Simons L.A.
        • Dwyer T.
        • Simons J.
        • Bernstein L.
        • Mock P.
        • Poonia N.S.
        • et al.
        Chylomicrons and chylomicron remnants in coronary artery disease: a case–control study.
        Atheroscelerosis. 1987; 65: 181-189
        • Karpe F.
        • Steiner G.
        • Uffelman K.
        • Olivecrona T.
        • Hamsten A.
        Postprandial lipoproteins and progression of coronary atherosclerosis.
        Atherosclerosis. 1994; 106: 83-97
        • Meyer E.
        • Westerveld H.T.
        • de Ruyter-Meijstek F.C.
        Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case–control study.
        Atherosclerosis. 1996; 124: 221-235
        • Mero N.
        • Malmström R.
        • Steiner G.
        • Taskinen M.R.
        • Syvänne M.
        Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease.
        Atherosclerosis. 2000; 150: 167-177
        • Groot P.H.
        • van Stiphout W.A.
        • Krauss X.H.
        • Jansen H.
        • Van Tol A.
        • van Ramshorst E.
        • et al.
        Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.
        Arterioscler. Thromb. 1991; 11: 653-662